STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3980 by analyst upside · 2026-08-14
FBRX
Forte Biosciences, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
-4.0%
implied upside to consensus target
Current Price $76.86
Consensus Target $73.8
Bull Target $77.0
Bear Target $61.0
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
4
Sell
0
52-Week Low $9.91
52-Week High $77.2
YTD Return +225.5%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.57
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $9.91
52-Week High $77.2
Current Price $76.86
Bear Target $61.0
Bull Target $77.0
● Now $76.86 ● Target $73.8
TRADING DATA
Avg Volume 1.1M
YTD Return +225.5%
Analyst Count 5
Consensus Hold
Upside to Target -4.0%
Last Updated 2026-08-14

ANALYST SUMMARY

Forte Biosciences, Inc. (FBRX) is currently trading at $76.86 with a Wall Street consensus price target of $73.8, which is 4.0% below the current price over the next 12 months. 5 analysts currently cover FBRX, with a consensus rating of Hold - 20% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $77.0, while the most cautious has a target of $61.0.

FBRX operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 225.5% year-to-date and is currently trading near the upper end of its 52-week range of $9.91 – $77.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for FBRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group ● Initiated
Outperform 2025-11-25 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-11-17 33% win rate (6 calls)
Guggenheim ● Initiated
Buy 2025-08-18 62% win rate (8 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-08-15 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-06-24 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-04-01 33% win rate (6 calls)
TD Cowen ● Initiated
Buy 2025-01-21 Building track record
Chardan Capital - Reiterated
Buy → Buy 2024-12-04 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
14/30
Consensus clarity
26/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →